NEUROREGENESIS
DEAD

Serial Number

87288032

Owner

Farshchian, Alimorad

Attorney

Romy B. Jurado

First Use Date

Aug 1, 2016

Filing Date

Jan 3, 2017

Add to watchlist:

No watchlists yet
View on USPTO

NEUROREGENESIS Trademark

Serial Number: 87288032 • Registration: 5399383

NEUROREGENESIS is a trademark filed by Farshchian, Alimorad on January 3, 2017. The trademark is classified under Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Farshchian, Alimorad (3 trademarks)

1001 N.E. 125th Street
North Miami, FL 33161

Entity Type: 01

Trademark Details

Filing Date

January 3, 2017

Registration Date

February 13, 2018

First Use Anywhere

August 1, 2016

First Use in Commerce

August 1, 2016

Published for Opposition

November 28, 2017

Cancellation Date

August 23, 2024

Goods & Services

Medical services, namely, treating arthritis, neurodegenerative conditions, ophthalmological conditions, Chronic obstructive pulmonary disease, Parkinson's, dementia, brain trauma; medical consultations in the field of arthritis, neurodegenerative conditions, ophthalmological conditions, Chronic obstructive pulmonary disease, Parkinson's, dementia, brain trauma; medical clinics, namely, treatment of arthritis, neurodegenerative conditions, ophthalmological conditions, Chronic obstructive pulmonary disease, Parkinson's, dementia, brain trauma; medical services, namely, providing medical treatment to individuals with genetic diseases; providing medical therapies in the nature of infusion therapy services and blood therapy services; biomedical services, namely, collecting, screening and typing of human tissue, blood, blood components and stem cells for ultimate use in medical treatment and diagnosis; biomedical services, namely, testing of human tissue, blood, blood components and stem cells for treating and diagnosing genetic diseases; biomedical storage services, namely, human tissue banks, blood banks, blood component banks and stem cell banks for medical purposes; autologous blood therapies for the treatment of blood diseases and conditions; medical services in the field of stem cell therapy, namely, treatment of arthritis, neurodegenerative conditions, ophthalmological conditions, Chronic obstructive pulmonary disease, Parkinson's, dementia, brain trauma

Filing History

CANCELLED SEC. 8 (6-YR)
Aug 23, 2024 C8..
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Feb 13, 2023 REM1
REGISTERED-PRINCIPAL REGISTER
Feb 13, 2018 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 28, 2017 NPUB
PUBLISHED FOR OPPOSITION
Nov 28, 2017 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 8, 2017 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 20, 2017 CNSA
EXAMINER'S AMENDMENT ENTERED
Oct 20, 2017 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 20, 2017 GNEN
EXAMINERS AMENDMENT E-MAILED
Oct 20, 2017 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 20, 2017 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 29, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 29, 2017 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 29, 2017 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 3, 2017 GNRN
NON-FINAL ACTION E-MAILED
Apr 3, 2017 GNRT
NON-FINAL ACTION WRITTEN
Apr 3, 2017 CNRT
ASSIGNED TO EXAMINER
Mar 28, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 12, 2017 NWOS
NEW APPLICATION ENTERED
Jan 6, 2017 NWAP